Research output per year
Research output per year
Personal profile
Research interests
Extensive research experiences and interests in designing, implementing, and analyzing clinical trials in Alzheimer disease, especially for dominantly inherited Alzheimer disease.
Fingerprint
Dive into the research topics where Guoqiao Wang is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease
for the DIAN-TU Study Team, 2023, (Accepted/In press) In: European Journal of Nuclear Medicine and Molecular Imaging.Research output: Contribution to journal › Article › peer-review
-
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
For the Dominantly Inherited Alzheimer Network Trials Unit, Nov 2022, In: Annals of neurology. 92, 5, p. 729-744 16 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Avoid or Embrace? Practice Effects in Alzheimer’s Disease Prevention Trials
the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), Jun 16 2022, In: Frontiers in Aging Neuroscience. 14, 883131.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Comparing statistical methods in assessing the prognostic effect of biomarker variability on time-to-event clinical outcomes
Gao, F., Luo, J., Liu, J., Wan, F., Wang, G., Gordon, M. & Xiong, C., Dec 2022, In: BMC Medical Research Methodology. 22, 1, 201.Research output: Contribution to journal › Article › peer-review
Open Access -
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
for the DIAN-TU Study Team, 2022, In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 14, 1, e12367.Research output: Contribution to journal › Article › peer-review
Open Access